Crowdonomics
This isn’t NowRx’s most recent raise. NowRx Preferred Equity 1 (Closed) is more current.View latest round
NowRx

Reg A Offering (2019)

ClosedReached targetReg A+Preferred Equity
via SeedInvest · last checked Sep 7, 2026View campaign
Raised
$20M
100% of ceiling · target hit day 164
Investors
8,918
$2.2K avg
Post-money valuation
$85M
pre-money + amount raised

Raised over time

Cumulative raisedInvestors
$20.0M$10.0M$0
8.9K4.5K0
Aug 14, 2019 · openedJun 19, 2020 · last reading
Target ($1.5M) hit — Jan 25, 2020, day 164$10.0M raised — May 14, 2020

Left axis: cumulative dollars raised. Right axis: cumulative investors. Live figures via SeedInvest, last checked Sep 7, 2026; investor counts may lag the platform by up to a day.

Financials disclosed in this offering

No financial statements linked to this round

The issuer's filing for this offering hasn't been parsed into fiscal-year statements yet.

Amendments to this offering

2 amendments
  1. Sep 16, 2019
    Terms not yet extracted from this filing
    Form 1-A/A on EDGAR ↗
  2. Sep 13, 2019
    Terms not yet extracted from this filing
    Form 1-A/A on EDGAR ↗

Each line compares the amendment with the previous filing of this offering. Form 1-A amendments state no reason; those filed before qualification are usually responses to SEC staff review.

Deal terms

Pre-money$65M
Post-money$85M
Price / share$3.4477

Offering details

Target$1,500,000
Max—
Min investment$1,000
OpenedAug 14, 2019
Deadline—
ClosedJun 19, 2020
Days active310

Links & provenance

Campaign pageSEC filing
Source: SEC EDGAR
0001144204-19-040140
Last synced Sep 7, 2026

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.